Cellceutix Signs Lab Services Research Support Agreement with Dana Farber/Partners CancerCare, Inc.

BEVERLY, MA–(Marketwire – Sep 21, 2011) – Cellceutix Corporation (OTCQB: CTIX) (PINKSHEETS: CTIX), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, reported today that it has signed a Laboratory Services Research Support Agreement with Dana Farber/Partners CancerCare, Inc. The agreement outlines the collaborative and laboratory support for the planned clinical trials for Kevetrin™, Cellceutix’s novel compound as an indication for cancer.

About Dana-Farber/Harvard Cancer Center

More information on Dana-Farber/Harvard Cancer Center can be found at http://www.dfhcc.harvard.edu/